Latest News
Veracyte, Inc.
- Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT)
- Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com
- Veracyte director Muna Bhanji sells $81,456 in company stock By Investing.com
- Veracyte Nabs Medicare Reimbursement for Prosigna Breast Cancer Recurrence Risk Test
- Veracyte Inc. Q3FY26 Results: Release date set for November 4
- Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
- Veracyte Inc (VCYT) Shares Fall 6.3% -- What GF Score of 79 Tells Investors
- Cathie Wood’s ARK sells Teradyne stock, buys Veracyte
- A Look at Veracyte Inc (VCYT) After 4.1% Gain -- GF Value $39.27 vs Price $47.67
- Veracyte Inc (VCYT) Stock Down 4.0% but Still Overvalued -- GF S
- University Hospitals Seidman Cancer Center researchers Demonstrate Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
- Veracyte’s Decipher test shows predictive value in prostate cancer By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →